Proactive Investors - Run By Investors For Investors

CymaBay stock bombs after seladelpar disappoints in a study for its liver treatment

The California company’s NASH ambitions hit a wall as reductions in liver fat were minimal and not significant compared to placebo
A generic representation of a liver
CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases

CymaBay Therapeutics Inc (NASDAQ:CBAY) tumbled in pre-market trade Tuesday after the company’s lead drug, seladelpar, posted disappointing results in a mid-stage clinical trial linked to nonalcoholic steatohepatitis (NASH).

NASH is liver inflammation and damage caused by a buildup of fat in the liver. Patients with this disease are often told they have a "fatty liver."

In the Phase 2 study, three oral doses of seladelpar, all performed worse than a harmless placebo, based on a non-invasive imaging test that measures decreases in liver fat.

Investors sent shares in the Newark, California-based company down nearly 40.4% to $6.60 in pre-market trade.

READ: Shares of CymaBay Therapeutics gain after study signals Seladelpar treatment shows 'efficacy'

The study had enrolled 181 patients with moderate stage of NASH and treated them for 12 weeks.

Reductions in liver fat were minimal and “not significant” compared to a placebo, said the company in a statement.

“While the reductions in liver fat were minimal, we remain encouraged by the significant improvements in biochemical markers of liver injury that we observed at week 12,” said Dr Pol Boudes, chief medical officer at CymaBay Therapeutics.

Boudes said the 52-week liver biopsy data will allow the company to understand whether the improvement in liver injury markers will translate into histological, or microscopic improvement.

“The observed improvement in markers of liver injury are consistent with the observed effects of seladelpar in PBC and further support the potential for seladelpar to improve liver health,” said Boudes.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

View full CBAY profile View Profile

CymaBay Therapeutics Timeline

Related Articles

February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
picture of a knee
May 20 2019
We take a closer look at Collagen Solutions, which received third-party validation of its business model in the form of outside investment from a blue-chip US agriculture company
young girl with allergy
April 29 2019
The sell-off that followed the recent disappointment of Allergy’s PQ Birch jab means now might be a good time to invest, according to City broker finnCap
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use